James Stephen Mccready Mortensen
Director of Finance/CFO bei CHEMRING GROUP PLC
Vermögen: 135 385 $ am 31.03.2024
Profil
James Stephen Mccready Mortensen is currently the Chief Financial Officer & Director at Chemring Group Plc since 2024.
He is also a Director at ICU Medical Group Ltd.
Additionally, he completed his undergraduate degree at the University of Bristol.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CHEMRING GROUP PLC
0,01% | 13.12.2023 | 29 524 ( 0,01% ) | 135 385 $ | 31.03.2024 |
Aktive Positionen von James Stephen Mccready Mortensen
| Unternehmen | Position | Beginn |
|---|---|---|
| CHEMRING GROUP PLC | Director of Finance/CFO | 01.01.2024 |
ICU Medical Group Ltd.
 ICU Medical Group Ltd. Medical SpecialtiesHealth Technology Part of ICU Medical, Inc., ICU Medical Group Ltd. is a British company that manufactures specialty medical devices. The private company is based in Ashford, UK. JehanZeb Noor has been the CEO of the company since 2019. ICU Medical Group was acquired by ICU Medical, Inc. from Smiths Group Plc on January 06, 2022 for $3,460.41 million. | Director/Board Member | - |
Ausbildung von James Stephen Mccready Mortensen
| University of Bristol | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CHEMRING GROUP PLC | Electronic Technology |
| Private Unternehmen | 1 |
|---|---|
ICU Medical Group Ltd.
ICU Medical Group Ltd. Medical SpecialtiesHealth Technology Part of ICU Medical, Inc., ICU Medical Group Ltd. is a British company that manufactures specialty medical devices. The private company is based in Ashford, UK. JehanZeb Noor has been the CEO of the company since 2019. ICU Medical Group was acquired by ICU Medical, Inc. from Smiths Group Plc on January 06, 2022 for $3,460.41 million. | Health Technology |
